IL163578A0 - Use of the mal protein as a tumour marker - Google Patents

Use of the mal protein as a tumour marker

Info

Publication number
IL163578A0
IL163578A0 IL16357803A IL16357803A IL163578A0 IL 163578 A0 IL163578 A0 IL 163578A0 IL 16357803 A IL16357803 A IL 16357803A IL 16357803 A IL16357803 A IL 16357803A IL 163578 A0 IL163578 A0 IL 163578A0
Authority
IL
Israel
Prior art keywords
tumour marker
mal protein
mal
protein
tumour
Prior art date
Application number
IL16357803A
Other languages
English (en)
Original Assignee
Consejo Superior Investigacion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion filed Critical Consejo Superior Investigacion
Publication of IL163578A0 publication Critical patent/IL163578A0/xx

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57438Specifically defined cancers of liver, pancreas or kidney
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL16357803A 2002-03-14 2003-03-14 Use of the mal protein as a tumour marker IL163578A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200200615A ES2200678B1 (es) 2002-03-14 2002-03-14 Uso de la proteina mal como marcador tumoral.
PCT/ES2003/000119 WO2003076948A1 (es) 2002-03-14 2003-03-14 Uso de la proteina mal como marcador tumoral

Publications (1)

Publication Number Publication Date
IL163578A0 true IL163578A0 (en) 2005-12-18

Family

ID=27799028

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16357803A IL163578A0 (en) 2002-03-14 2003-03-14 Use of the mal protein as a tumour marker

Country Status (11)

Country Link
EP (1) EP1930728A1 (es)
JP (1) JP2005520135A (es)
KR (1) KR20040105771A (es)
CN (1) CN1643380A (es)
AU (1) AU2003216926A1 (es)
CA (1) CA2476767A1 (es)
ES (1) ES2200678B1 (es)
IL (1) IL163578A0 (es)
MX (1) MXPA04008962A (es)
RU (1) RU2004129773A (es)
WO (1) WO2003076948A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018316343A1 (en) 2017-08-11 2020-02-13 Genentech, Inc. Anti-CD8 antibodies and uses thereof
JP2022517917A (ja) * 2018-12-28 2022-03-11 ネオゼンティーシー コーポレーション Malが発現された幹細胞様メモリーt細胞を有効成分として含む免疫増強又は抗癌活性促進用の組成物
KR102179381B1 (ko) * 2018-12-28 2020-11-16 주식회사 네오젠티씨 Mal이 발현된 줄기세포 유사 기억 t 세포를 유효성분으로 포함하는 면역증강 또는 항암활성 증진용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2395054A1 (en) * 2000-01-18 2001-07-26 Human Genome Sciences, Inc. Human polynucleotides, polypeptides, and antibodies

Also Published As

Publication number Publication date
RU2004129773A (ru) 2005-05-10
ES2200678B1 (es) 2005-06-01
ES2200678A1 (es) 2004-03-01
MXPA04008962A (es) 2005-06-03
WO2003076948A1 (es) 2003-09-18
JP2005520135A (ja) 2005-07-07
CA2476767A1 (en) 2003-09-18
AU2003216926A1 (en) 2003-09-22
CN1643380A (zh) 2005-07-20
KR20040105771A (ko) 2004-12-16
EP1930728A1 (en) 2008-06-11

Similar Documents

Publication Publication Date Title
EP1514106A4 (en) TARGETED THERAPEUTIC PROTEINS
AU2003289603A1 (en) Tumor vaccine
GB0219660D0 (en) Therapeutic use
AU2003226899A8 (en) Human diabetes-mediating proteins
GB2394697B (en) Marker pens
AU2003298582A8 (en) Therapeutic guanidines
IL163578A0 (en) Use of the mal protein as a tumour marker
AU2003213146A8 (en) Activated protein c formulations
GB2406644B (en) Viral marker
GB0223982D0 (en) Marker gene
GB0204720D0 (en) Novel use
GB0210682D0 (en) Novel use
GB0228704D0 (en) Novel therapeutic target
GB0213383D0 (en) Therapeutic conditions
GB0221853D0 (en) Animal scarer
GB0218699D0 (en) Animal spooker
GB0226865D0 (en) Therapeutic use
GB0223118D0 (en) Therapeutic use
GB0224787D0 (en) Therapeutic use
GB0226850D0 (en) Therapeutic use
GB0228703D0 (en) Novel therapeutic target
GB0228695D0 (en) Novel therapeutic target
GB0228697D0 (en) Novel therapeutic target
GB0228701D0 (en) Novel therapeutic target
GB0228707D0 (en) Novel therapeutic target